SCHEMBL23332791

SCHEMBL23332791

C=C(CCNC(=O)COC1CCC1)NC(=O)COc1ccc(Cl)cc1

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ATF4 P18848 8/20 0.60
▸ CYP1A2 P05177 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ BCHE P06276 1/20 0.43
▸ ACHE P22303 1/20 0.43
▸ ADAMTS4 O75173 1/20 0.42
▸ MMP8 P22894 1/20 0.42
▸ ADAMTS5 Q9UNA0 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23383657 0.98 ATF4 (0.60) ATF4CYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL23384143 0.97 ATF4 (0.59) ATF4CYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL23383769 0.96 ATF4 (0.58) ATF4CYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL23182908 0.88 KDM4E (0.54) ATF4CYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL23332720 0.88 ATF4 (0.47) ATF4CYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL23332739 0.88 ATF4 (0.47) ATF4CYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL23333253 0.87 ATF4 (0.48) ATF4CYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL23332793 0.87 ATF4 (0.48) ATF4CYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL23332725 0.87 ATF4 (0.48) ATF4CYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL25962498 0.87 ATF4 (0.48) ATF4CYP1A2CYP2C9CYP2C19KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210130308-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 DENALI THERAPEUTICS INC. 2021-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210130308-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 EIF2A, EIF4A2, EIF4EBP1 ATF4 118/4885CYP1A2 4419/4885CYP2C9 4857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback